Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The company's advanced-stage product candidate is Roclatan, a once-daily eye drop to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AERI
Previous Symbol
CUSIPN/A
Phone919-237-5300
Debt
Debt-to-Equity RatioN/A
Current Ratio7.05
Quick Ratio6.89
Price-To-Earnings
Trailing P/E Ratio-11.34
Forward P/E Ratio-6.97
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$3.60 per share
Price / Book10.62
Profitability
EPS (Most Recent Fiscal Year)($3.37)
Net Income$-145,100,000.00
Net MarginsN/A
Return on Equity-106.13%
Return on Assets-65.99%
Miscellaneous
Employees160
Outstanding Shares45,450,000
Market Cap$1.77 billion
OptionableOptionable
Aerie Pharmaceuticals (NASDAQ:AERI) Frequently Asked Questions
What is Aerie Pharmaceuticals' stock symbol?
Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."
How were Aerie Pharmaceuticals' earnings last quarter?
Aerie Pharmaceuticals Inc (NASDAQ:AERI) issued its quarterly earnings data on Tuesday, November, 6th. The company reported ($1.73) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.33) by $0.40. The firm earned $7.30 million during the quarter, compared to analyst estimates of $5.63 million. View Aerie Pharmaceuticals' Earnings History.
When is Aerie Pharmaceuticals' next earnings date?
What price target have analysts set for AERI?
11 Wall Street analysts have issued 12-month price targets for Aerie Pharmaceuticals' shares. Their predictions range from $64.00 to $105.00. On average, they anticipate Aerie Pharmaceuticals' stock price to reach $81.00 in the next year. This suggests a possible upside of 111.9% from the stock's current price. View Analyst Price Targets for Aerie Pharmaceuticals.
What is the consensus analysts' recommendation for Aerie Pharmaceuticals?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aerie Pharmaceuticals in the last year. There are currently 1 sell rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aerie Pharmaceuticals.
What are Wall Street analysts saying about Aerie Pharmaceuticals stock?
Here are some recent quotes from research analysts about Aerie Pharmaceuticals stock:
- 1. Mizuho analysts commented, "We note that one or two weeks of data can have a meaningful impact on our total 2018 projections and we used what we believe are conservative assumptions. We believe there could be upside to our current estimate and we believe the risk of Aerie not delivering on its 2018 sales guidance of $20-30 mil is low." (11/27/2018)
- 2. According to Zacks Investment Research, "The FDA approval of Aerie’s lead drug, Rhopressa is a significant boost for the company. The solid uptake in prescription volumes post launch should propel sales as glaucoma is one of the largest segments in the global ophthalmic market. Aerie is also evaluating Roclatan, a once-daily, quadruple action fixed-dose combination of Rhopressa and Xalatan. Aerie recently submitted its NDA for Roclatan to the FDA and expects a review period of ten months. A tentative approval will boost the growth prospects. However, Rhopressa faces stiff competition from established branded and generic pharmaceutical companies, such as Novartis’ Simbrinza and Travtan, and Allergan’s Lumigan and Vyzulta among others. Hence, Rhopressa will face a tough time in gaining market share due to competition from these products. Shares have underperformed the industry in the year so far." (10/10/2018)
- 3. Cantor Fitzgerald analysts commented, "We rate Aerie Pharmaceuticals Overweight. AERI commercializes and develops once- daily eye drops Rhopressa and Roclatan, respectively, for glaucoma. Rhopressa is the first novel drug in a market that has not seen innovation in 20 years. Valuation Summary We value Aerie based on the NPV of the cash flows associated with its glaucoma drug candidates. Our price target is $86/share." (10/2/2018)
- 4. Canaccord Genuity analysts commented, "We hosted Aerie CFO a fireside chat this afternoon at the Canaccord Genuity Growth Conference. Aerie is an ophthalmology company that recently launched Rhopressa, the first new class of glaucoma drugs in over twenty years. In addition to Rhopressa, Aerie plans to commercialize Roclatan, a combination of Rhopressa and latanoprost, the leading glaucoma therapy in the US market. Beyond glaucoma, Aerie is exploring the use of ROCK inhibitors in back-of-the-eye conditions like wet AMD and could explore opportunities to utilize ROCK inhibitors outside of ophthalmology. Rhopressa tracking well with strong user feedback. Launched earlier this year, Rhopressa is already gaining traction with ophthalmologists and patients, and Aerie is pleased with the current uptake trajectory." (8/10/2018)
Has Aerie Pharmaceuticals been receiving favorable news coverage?
Press coverage about AERI stock has been trending somewhat positive on Saturday, InfoTrie reports. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aerie Pharmaceuticals earned a news impact score of 1.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 9.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days.
Who are some of Aerie Pharmaceuticals' key competitors?
Some companies that are related to Aerie Pharmaceuticals include Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), bluebird bio (BLUE), Ablynx (ABLYF), argenx (ARGX), Allogene Therapeutics (ALLO), Repligen (RGEN), China Biologic Products (CBPO), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Atara Biotherapeutics (ATRA), Denali Therapeutics (DNLI), Crispr Therapeutics (CRSP), Regenxbio (RGNX) and Spark Therapeutics (ONCE).
Who are Aerie Pharmaceuticals' key executives?
Aerie Pharmaceuticals' management team includes the folowing people:
- Dr. Vicente J. Anido Jr., CEO & Chairman (Age 65)
- Mr. Thomas A. Mitro, Pres & COO (Age 60)
- Dr. Casey C. Kopczynski, Co-Founder & Chief Scientific Officer (Age 57)
- Mr. Richard James Rubino CPA, CFO, Sec. & Treasurer (Age 60)
- Ms. Jessica Crespo CPA, Director of Accounting
Who are Aerie Pharmaceuticals' major shareholders?
Aerie Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.55%), Vanguard Group Inc (8.55%), BlackRock Inc. (6.91%), Partner Fund Management L.P. (4.97%), Jennison Associates LLC (3.07%) and HealthCor Management L.P. (2.27%). Company insiders that own Aerie Pharmaceuticals stock include Casey C Kopczynski, Foresite Capital Fund Ii, LP, Geoffrey M Duyk, Gerald D Cagle, Richard J Rubino, Thomas A Mitro and Vicente Anido Jr. View Institutional Ownership Trends for Aerie Pharmaceuticals.
Which institutional investors are selling Aerie Pharmaceuticals stock?
AERI stock was sold by a variety of institutional investors in the last quarter, including Partner Fund Management L.P., HealthCor Management L.P., FMR LLC, Morgan Stanley, Pictet Asset Management Ltd., Marshall Wace North America L.P., Jane Street Group LLC and Thrivent Financial for Lutherans. Company insiders that have sold Aerie Pharmaceuticals company stock in the last year include Casey C Kopczynski, Richard J Rubino, Thomas A Mitro and Vicente Anido Jr. View Insider Buying and Selling for Aerie Pharmaceuticals.
Which institutional investors are buying Aerie Pharmaceuticals stock?
AERI stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc, Vanguard Group Inc., Provident Investment Management Inc., Candriam Luxembourg S.C.A., Frontier Capital Management Co. LLC, Kornitzer Capital Management Inc. KS, BlackRock Inc. and Russell Investments Group Ltd.. View Insider Buying and Selling for Aerie Pharmaceuticals.
How do I buy shares of Aerie Pharmaceuticals?
Shares of AERI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aerie Pharmaceuticals' stock price today?
One share of AERI stock can currently be purchased for approximately $38.22.
How big of a company is Aerie Pharmaceuticals?
Aerie Pharmaceuticals has a market capitalization of $1.77 billion. The company earns $-145,100,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis. Aerie Pharmaceuticals employs 160 workers across the globe.
What is Aerie Pharmaceuticals' official website?
How can I contact Aerie Pharmaceuticals?
Aerie Pharmaceuticals' mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The company can be reached via phone at 919-237-5300 or via email at [email protected]
MarketBeat Community Rating for Aerie Pharmaceuticals (NASDAQ AERI)
MarketBeat's community ratings are surveys of what our community members think about Aerie Pharmaceuticals and other stocks. Vote "Outperform" if you believe AERI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AERI will underperform the S&P 500 over the long term. You may vote once every thirty days.
